Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants

European Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2013, Pages 1321-1329

  Nara, Miho ^a   Takahashi, Naoto ^a   Miura, Masatomo ^b   Niioka, Takenori ^b   Kagaya, Hideaki ^b   Fujishima, Naohito ^b   Saitoh, Hirobumi ^a   Kameoka, Yoshihiro ^a   Tagawa, Hiroyuki ^a   Hirokawa, Makoto ^b   Sawada, Kenichi ^a  

^a AKITA UNIVERSITY   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Blood concentration; Cyclosporine; Itraconazole; Tacrolimus

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A5; HYDROXYITRACONAZOLE; ITRACONAZOLE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; JAPANESE; LOADING DRUG DOSE; MALE; MYCOSIS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; RELIABILITY; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITRACONAZOLE; JAPAN; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84878013836     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1471-2     Document Type: Article

References (31)

1. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43(10):623-653
2. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74(3):245-254. doi: 10.1016/S0009-9236(03)00168-1
3. Roy JN, Barama A, Poirier C, Vinet B, Roger M (2006) Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genom 16(9):659-665. doi: 10.1097/01.fpc.0000220571. 20961.dd
4. Hesselink DA, van Gelder T, van Schaik RH (2005) The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6(4):323-337. doi: 10.1517/14622416.6.4.323
5. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138(9):705-713
6. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103(4):1527-1533. doi: 10.1182/blood-2003-08-2644
7. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38(2):111-180
8. Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28(9):1805-1808
9. Koks CH, Meenhorst PL, Bult A, Beijnen JH (2002) Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. Pharmacol Res 46(2):195-201
10. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos: Biol Fate Chem 32(10):1121-1131. doi: 10.1124/dmd.104.000315
11. Buchkowsky SS, Partovi N, Ensom MH (2005) Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit 27(3):322-333
12. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56(6 Pt 1):601-607
13. Jalava KM, Olkkola KT, Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61(4):410-415. doi: 10.1016/S0009-9236(97)90191-0
14. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos: Biol Fate Chem 32(12):1434-1445. doi: 10.1124/dmd.104.001313
15. Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T (2010) Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol 69(6):593-597. doi: 10.1111/j.1365-2125.2010. 03656.x
16. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9):773-779
17. Nara M, Takahashi N, Miura M, Saitoh H, Kagaya H, Sawada K (2010) Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. Am J Hematol 85(8):634-635. doi: 10.1002/ajh.21759
18. Wallemacq P, Maine GT, Berg K, Rosiere T, Marquet P, Aimo G, Mengozzi G, Young J, Wonigeit K, Kretschmer R, Wermuth B, Schmid RW (2010) Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay. Ther Drug Monit 32(2):145-151. doi: 10.1097/FTD.0b013e3181d46386
19. Amann S, Parker TS, Levine DM (2009) Evaluation of 2 immunoassays for monitoring low blood levels of tacrolimus. Ther Drug Monit 31(2):273-276. doi: 10.1097/FTD.0b013e318196dfed
20. Miura M, Takahashi N, Nara M, Fujishima N, Kagaya H, Kameoka Y, Saitoh H, Tagawa H, Sawada K (2010) A simple, sensitive high-performance liquid chromatography-ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. Ann Clin Biochem 47(Pt 5):432-439. doi: 10.1258/acb.2010.010029
21. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population. Pharmacogenetics 12(4):331-334
22. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6):825-828
23. Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G (2011) Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 12(9):1293-1303. doi: 10.2217/pgs.11.70
24. Anglicheau D, Legendre C, Beaune P, Thervet E (2007) Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8(7):835-849. doi: 10.2217/14622416.8.7.835
25. Leather H, Boyette RM, Tian L, Wingard JR (2006) Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12(3):325-334. doi: 10.1016/j.bbmt.2005.10.022
26. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K (2006) Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 16(2):119-127
27. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83(1):77-85. doi: 10.1038/sj.clpt.6100230
28. Amundsen R, Asberg A, Ohm IK, Christensen H (2012) Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab Dispos: Biol Fate Chem 40(4):655-661. doi: 10.1124/dmd.111.043018
29. Keogh JP, Kunta JR (2006) Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27(5):543-554. doi: 10.1016/j.ejps.2005.11.011
30. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG (2005) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78(2):191-201. doi: 10.1016/j.clpt.2005.04.012
31. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84(21):7735-7738